JAK-2-/3-IN-3 (compound ST4j) can be used in lymph derived diseases and leukemia research. JAK-2-/3-IN-3 inhibits JAK2 autophosphorylation and induces apoptosis in a time- and dose-dependent manner. JAK-2-/3-IN-3 is a potent inhibitor of JAK2/3 with IC50 values of 13.00 and 14.86 nM for JAK2 and JAK3, respectively [1].

JAK-2/3-IN-3 (0-100 μM; 72 h) specifically inhibits human erythroleukemia cells with low toxicity to the normal cells [1]. JAK-2/3-IN-3 inhibits human erythroleukemia TF1 cell growth via the JAK2/STAT5 signaling pathway [1]. JAK-2/3-IN-3 (15.53 μM; 24, 48, 72 h) induces cytotoxicity via apoptosis in a time-dependent manner in TF1 cells [1]. JAK-2/3-IN-3 (IC 25, IC 50, IC 75; 24 h) induces cytotoxicity via apoptosis in a dose-dependent manner in TF1 cells [1]. Apoptosis Analysis [1] Cell Line: TF1 cells Concentration: 15.53 μM Incubation Time: 24, 48, 72 h Result: Increased cells apoptotic by ～20%, ～40% and ～70%, after 24-, 48- and 72-h incubations, respectively. Increased cells apoptotic by ～15%, 20%, and 30% with concentration of IC 25, IC 50 and IC 75, respectively. Cell Cytotoxicity Assay [1] Cell Line: TF1, HEL, Vero and HepG2 cells Concentration: 0-100 μM Incubation Time: 72 h Result: Inhibited growth of TF1 and HEL cells, with IC 50 s of 15.53 and 17.90 μM. Showed low toxic to normal Vero cells and HepG2 cells (IC 50 of >100 μM in Vero cells and of >50 μM in HepG2 cells).